Format

Send to

Choose Destination
Expert Opin Pharmacother. 2013 Dec;14(17):2351-60. doi: 10.1517/14656566.2013.837450. Epub 2013 Sep 19.

Chronic rhinosinusitis: an update on current pharmacotherapy.

Author information

1
Academic Medical Center, Department of Otorhinolaryngology , Meibergdreef 9, Postbus 22660, 1100 DD Amsterdam , The Netherlands +31 6 55 370 202 ; +31 206 913 850 ; G.F.Adriaensen@amc.uva.nl ; Gwijde@gmail.com.

Abstract

INTRODUCTION:

Chronic rhinosinusitis (CRS) is an inflammatory disease of the nasal and paranasal mucosa with great impact on quality of life and a large financial burden on society. This article provides an overview of its current and future pharmacotherapy, the mainstay of CRS treatment.

AREAS COVERED:

This article reviews the etiology, antibiotic and corticosteroid treatment, nasal irrigation therapy, bacterial lysates, anti-immunoglobulin E and anti-interleukin-5 therapy of CRS. This review highlights articles of interest on these topics in the PubMed database. Studies not in English language were excluded.

EXPERT OPINION:

CRS is a spectrum of disease characterized by mucosal inflammation. Defining its various subtypes will change its medical treatment from general anti-inflammatory medicine towards tailor-made pharmacotherapy. The optimal timing of endoscopic sinus surgery in this treatment process remains to be defined.

PMID:
24050707
DOI:
10.1517/14656566.2013.837450
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center